{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:01:41Z","timestamp":1761580901928},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.eururo.2011.07.037","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T07:19:57Z","timestamp":1311578397000},"page":"1163-1170","source":"Crossref","is-referenced-by-count":39,"title":["Sequence Therapy in Patients with Metastatic Renal Cell Carcinoma: Comparison of Common Targeted Treatment Options Following Failure of Receptor Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"60","author":[{"given":"Jonas","family":"Busch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Kempkensteffen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Johannsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingmar","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Hinz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Magheli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Weikert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2011.07.037_bib0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2407-9-34","article-title":"Metastatic renal cell cancer treatments: an indirect comparison meta-analysis","volume":"9","author":"Mills","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2011.07.037_bib0010","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.bjc.6605167","article-title":"Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness","volume":"101","author":"Thompson Coon","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2011.07.037_bib0015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2011.07.037_bib0020","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2010.06.032","article-title":"EAU guidelines on renal cell carcinoma: the 2010 update","volume":"58","author":"Ljungberg","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.037_bib0025","doi-asserted-by":"crossref","first-page":"618","DOI":"10.6004\/jnccn.2009.0043","article-title":"NCCN clinical practice guidelines in oncology: kidney cancer","volume":"7","author":"Motzer","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2011.07.037_bib0030","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1200\/JCO.2009.22.6480","article-title":"Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer","volume":"27","author":"Di Lorenzo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.07.037_bib0035","doi-asserted-by":"crossref","unstructured":"Elfiky AA, Cho DC, McDermott DF, et al. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urol Oncol. In press. DOI:10.1016\/j.urolonc.2010.01.008.","DOI":"10.1016\/j.urolonc.2010.01.008"},{"key":"10.1016\/j.eururo.2011.07.037_bib0040","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.eururo.2008.07.051","article-title":"Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis","volume":"54","author":"Eichelberg","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.037_bib0045","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1002\/cncr.25327","article-title":"Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab","volume":"116","author":"Garcia","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.07.037_bib0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.juro.2009.02.119","article-title":"Sequential sorafenib and sunitinib for renal cell carcinoma","volume":"182","author":"Sablin","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.07.037_bib0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cncr.24009","article-title":"Sequential therapy with sorafenib and sunitinib in renal cell carcinoma","volume":"115","author":"Dudek","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.07.037_bib0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00345-011-0673-4","article-title":"Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma","volume":"29","author":"Herrmann","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2011.07.037_bib0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2011.07.037_bib0070","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.07.037_bib0075","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.urology.2009.12.031","article-title":"Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy","volume":"76","author":"Vickers","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.07.037_bib0080","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.eururo.2010.09.008","article-title":"Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma","volume":"58","author":"Di Lorenzo","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.037_bib0085","doi-asserted-by":"crossref","unstructured":"Porta C, Procopio G, Carteni G, et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. In press. DOI:10.1111\/j.1464-410X.2011.10186.x.","DOI":"10.1111\/j.1464-410X.2011.10186.x"},{"key":"10.1016\/j.eururo.2011.07.037_bib0090","doi-asserted-by":"crossref","unstructured":"Buchler T, Klapka R, Melichar B, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma\u2014data from the Czech registry. Ann Oncol. In press.","DOI":"10.1093\/annonc\/mdr065"},{"key":"10.1016\/j.eururo.2011.07.037_bib0095","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.07.037_bib0100","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.eururo.2011.01.002","article-title":"Toxicities of targeted therapy and their management in kidney cancer","volume":"59","author":"Di Lorenzo","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.037_bib0105","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","article-title":"Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma","volume":"53","author":"Bhojani","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.037_bib0110","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2011.07.037_bib0115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.critrevonc.2010.07.018","article-title":"Sequential use of targeted agents in the treatment of renal cell carcinoma","volume":"77","author":"Hutson","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eururo.2011.07.037_bib0120","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/cncr.24239","article-title":"Targeting mTOR in renal cell carcinoma","volume":"115(Suppl)","author":"Hudes","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.07.037_bib0125","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1002\/cncr.25583","article-title":"Sunitinib rechallenge in metastatic renal cell carcinoma patients","volume":"116","author":"Zama","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.07.037_bib0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2009.02.007","article-title":"Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited","volume":"15","author":"Loges","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2011.07.037_bib0135","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2011.07.037_bib0140","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"Paez-Ribes","year":"2009","journal-title":"Cancer Cell"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811007755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811007755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T07:59:17Z","timestamp":1543651157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283811007755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0302283811007755"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2011.07.037","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}